Investor Relations

Latest News

Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

Event icon

Coporate Presentation

Mineralys Corporate Overview March 2023

Presentation icon

Upcoming Event

2023 Jefferies Healthcare Conference

Latest Financial Results

Q1 2023

Quarter Ended Mar 31, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

Mineralys Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company committed to developing treatments for diseases that are driven by abnormally elevated aldosterone. The Company’s clinical-stage product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor, licensed from Mitsubishi Tanabe Pharma Corporation (“Mitsubishi Tanabe”), that is being investigated for the treatment of hypertension. The Company has completed a Phase 2 proof-of-concept study in patients with uncontrolled hypertension and has plans for the continued research and development of lorundrostat in hypertension and other potential indications. The Company was incorporated as a Delaware corporation in May 2019, and it is headquartered in Radnor, Pennsylvania.

Stock Snapshot

Contact Information


Mineralys Therapeutics, Inc.
150 N. Radnor Chester Rd
Suite F200
Radnor, PA 19087
United States
Toll-Free: 888-378-6240

Transfer Agent

American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, New York 11219
United States
T: 800-937-5449
F: 718-236-2641


Elixir Health Public Relations
Tom Weible
T: 515-707-9678

Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.